| Accession |
PRJCA027155 |
| Title |
A randomized,open-label phase 3 study of combination Ami and carb-pem therapy,compared with Carb-Pem,in patients with EGFR Exon20ins mutated locally advanced or metastatic NSCLC |
| Relevance |
Medical |
| Data types |
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
This randomized, multicenter, Phase 3 study seeks to demostrate the improved efficacy of combining amivantamab with standard of care carboplatin-pemetrexed chemotherapy (Arm A0 compared with carboplatin-pemetrexed chemotherapy (Arm B) in the first-line treatment of patients with EGFR Exon 20ins NSCLC. |
| Sample scope |
Multiisolate |
| Release date |
2024-06-18 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| JANSSEN RESEARCH & DEVELOPMENT, LLC.
|
|
2020LP00568
|
|
|
|
| Submitter |
ling
zhang (shfkgcp@163.com)
|
| Organization |
shanghai pulmonary hospital |
| Submission date |
2024-06-18 |
